PDF(Pubmed)
Abstract：
The purpose of this study was to review the literature on the clinical use of voriconazole (VRC) in pediatric patients. MEDLINE, Embase, PubMed, Web of Science, and Cochrane Library were searched from January 1, 2000, to August 15, 2023 for relevant clinical studies on VRC use in pediatric patients. Data were collected based on inclusion and exclusion criteria, and a systematic review was performed on recent research related to the use of VRC in pediatric patients. This systematic review included a total of 35 observational studies among which there were 16 studies investigating factors influencing VRC plasma trough concentrations (Ctrough) in pediatric patients, 14 studies exploring VRC maintenance doses required to achieve target range of Ctrough, and 11 studies focusing on population pharmacokinetic (PPK) research of VRC in pediatric patients. Our study found that the Ctrough of VRC were influenced by both genetic and non-genetic factors. The optimal dosing of VRC was correlated with age in pediatric patients, and younger children usually required higher VRC doses to achieve target Ctrough compared to older children. Establishing a PPK model for VRC can assist in achieving more precise individualized dosing in children.
摘要：
目的对伏立康唑(VRC)在儿科患者中的临床应用进行文献综述。MEDLINE,Embase,PubMed,WebofScience,和Cochrane图书馆从2000年1月1日至2023年8月15日检索VRC在儿科患者中使用的相关临床研究。根据纳入和排除标准收集数据，并对近期在儿科患者中使用VRC的相关研究进行了系统评价.本系统综述共纳入35项观察性研究，其中有16项研究调查了影响儿科患者VRC血浆谷浓度（Ctalf）的因素。14项研究探索VRC维持剂量，以达到目标范围的Ctoor，以及11项研究，重点是VRC在儿科患者中的群体药代动力学（PPK）研究。我们的研究发现，VRC的Ctrugh受遗传和非遗传因素的影响。VRC的最佳剂量与儿科患者的年龄相关，与年龄较大的儿童相比，年龄较小的儿童通常需要更高的VRC剂量才能达到目标Ctugh。建立VRC的PPK模型可以帮助在儿童中实现更精确的个性化给药。
